3
Announcements
Trials
Browse
Landscape
Status
Completed
4
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Burkitt Lymphoma
14
Leukemia, Biphenotypic, Acute
9
Leukemia, Myeloid, Acute
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Osteosarcoma
3
Myelodysplastic Syndromes
3
Lymphoma
3
Breast Neoplasms
3
Blastic Plasmacytoid Dendritic Cell Neoplasm
3
Primary Myelofibrosis
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Leukemia, Large Granular Lymphocytic
2
Hematologic Neoplasms
2
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Polycythemia Vera
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Mouth Neoplasms
1
Meningeal Neoplasms
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
blinatumomab
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
Methotrexate
×
Clear all
NCT05959720
2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
180 enrolled